Clinical trial
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having…
NCT00067561 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00067561 |
|---|---|
| Title | Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy |
| Official title | A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects With Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Irritable Colon, Irritable Bowel Syndrome (IBS) |
| Intervention type | Drug |
| Interventions | Alosetron |
| Enrollment | 702 |
| Start date | Jun 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Aug 25, 2003 |
| Last update posted | Apr 16, 2015 |
| Countries | Australia, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: